The European Medicines Agency (EMA) is preparing to shed a third of its staff after Brexit when it moves its offices in London to Amsterdam. This was confirmed by EMA’s press services in a press release announcing a new slowdown in activities before the autumn.
The EMA’s task is to assess, oversee and monitor the safety of medicines marketed in the EU. On 20 November last, the member states decided to relocate the EMA to Amsterdam (Netherlands) in view of the United Kingdom leaving the...